(Q37539304)

20 August 2017

1 reference

title

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors (English)

1 reference

20 August 2017

author name string

Michalis V Karamouzis

series ordinal

1

1 reference

20 August 2017

Panagiotis A Konstantinopoulos

series ordinal

2

1 reference

20 August 2017

Athanasios G Papavassiliou

series ordinal

3

1 reference

20 August 2017

publication date

1 July 2009

1 reference

Lancet Oncology Commission

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

709-717

1 reference

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Tyrosine kinase receptor indistinguishable from the c-met protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

c-Met is essential for wound healing in the skin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

The Met tyrosine kinase receptor in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

The crossroads of oncogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Silencing the MET oncogene leads to regression of experimental tumors and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Drug development of MET inhibitors: targeting oncogene addiction and expedience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

MicroRNAs impair MET-mediated invasive growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Cross-talk between the proto-oncogenes Met and Ron

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Trastuzumab--mechanism of action and use

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

The Sema domain of Met is necessary for receptor dimerization and activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

High-throughput analysis of HGF-stimulated cell scattering

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

A new Met inhibitory-scaffold identified by a focused forward chemical biological screen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Prognostic significance of c-Met expression in glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970137-8

7 January 2021

10.1016/S1470-2045(09)70137-8

Identifiers

DOI

1 reference

20 August 2017

1 reference